title: Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia.
abstract: Donor lymphocyte infusion (DLI) was originally administered as a single, relatively large dose of lymphocytes called a bulk dose regimen (BDR). It has since been suggested that the use of an escalating dose regimen (EDR) may be equally effective against leukemia while it induces less graft-versus-host disease (GVHD). We therefore compared the efficacy and incidence of complications in a nonrandomized sequential study of the 2 regimens in 48 consecutive patients who had relapses with cytogenetic or hematologic evidence of chronic myeloid leukemia after allogeneic stem cell transplantation. Twenty-eight patients were treated on a BDR (August 1990 to November 1995) and 20 were treated on an EDR (December 1995 to January 1998). Although the probability of achieving cytogenetic remission within 2 years of starting DLI did not differ significantly between the 2 groups (EDR, 91% [CI, 63%-98%] vs. BDR, 67% [CI,49%-83%], P =.70), the incidence of GVHD was much lower using EDR (10% vs. 44%, P =.011). When we considered only subsets of patients treated by BDR or EDR who had received comparable total lymphoid cell doses, the incidence and severity of acute and chronic GVHD were both significantly lower for recipients treated by EDR than for recipients treated by BDR (P =.005 and P =.031, respectively). These findings suggest that the incidence of GVHD associated with the EDR is low, not because the final cell dose is small, but because lymphocytes are administered over a considerable number of months. (Blood. 2000;95:67-71)
authors.affiliation: Department of Haematology, Imperial College School of Medicine at Hammersmith Hospital, London, United Kingdom.
authors.forename: F
authors.initials: F
authors.lastname: Dazzi
authors.forename: R M
authors.initials: RM
authors.lastname: Szydlo
authors.forename: C
authors.initials: C
authors.lastname: Craddock
authors.forename: N C
authors.initials: NC
authors.lastname: Cross
authors.forename: J
authors.initials: J
authors.lastname: Kaeda
authors.forename: A
authors.initials: A
authors.lastname: Chase
authors.forename: E
authors.initials: E
authors.lastname: Olavarria
authors.forename: F
authors.initials: F
authors.lastname: van Rhee
authors.forename: E
authors.initials: E
authors.lastname: Kanfer
authors.forename: J F
authors.initials: JF
authors.lastname: Apperley
authors.forename: J M
authors.initials: JM
authors.lastname: Goldman
mesh_terms: D018572:Disease-Free Survival; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D006086:Graft vs Host Disease / Q000453:epidemiology / Q000517:prevention & control; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics / Q000628:therapy*; D017710:Lymphocyte Transfusion / Q000009:adverse effects; D008297:Male; D009679:Nuclear Family; D010677:Philadelphia Chromosome; D012333:RNA, Messenger / Q000235:genetics; D012008:Recurrence; D013997:Time Factors; D014184:Transplantation, Homologous
chemical_list: D012333:RNA, Messenger; D016044:Fusion Proteins, bcr-abl